(Total Views: 479)
Posted On: 03/13/2020 9:27:13 AM
Post# of 154082
Quote:
Company will file a modified trial protocol on Friday, March 13.
It will be interesting to learn how exactly the FDA wanted the protocol to be modified.
The last PR on the IND included this information:
Quote:
Leronlimab (PRO 140) will be administered subcutaneously as weekly dose of 700 mg.
I certainly hope the FDA did not ask CytoDyn to lower the dosage.
(1)
(0)
